Revolution Medicines, Inc. develops targeted oncology therapies for patients with RAS-addicted cancers. Company news centers on its RAS(ON) inhibitor pipeline, including daraxonrasib, a RAS(ON) multi-selective inhibitor, and selective programs such as elironrasib, zoldonrasib and RMC-5127.
Recurring updates cover clinical data in pancreatic ductal adenocarcinoma, non-small cell lung cancer and other RAS-mutant solid tumors, presentations at oncology meetings, scientific publications, regulatory interactions and trial-stage progress. Revolution Medicines also reports quarterly financial results, financing activity and corporate progress tied to research and development, potential commercialization planning and its broader RAS(ON) discovery platform.
Revolution Medicines (NASDAQ:RVMD) announced proposed public offerings of $750 million of common stock and $250 million aggregate principal amount of convertible senior notes due 2033, with underwriter overallotment options of $112.5 million and $37.5 million, respectively.
The notes will be senior unsecured, accrue interest semi-annually, be convertible under specified circumstances, and may be redeemable after May 6, 2030. Net proceeds are for general corporate purposes including R&D and commercialization expenses.
Revolution Medicines (NASDAQ:RVMD) reported positive topline Phase 3 RASolute 302 results in previously treated metastatic pancreatic ductal adenocarcinoma. Daraxonrasib oral once-daily met all primary and key secondary endpoints, showing median overall survival of 13.2 months vs. 6.7 months for chemotherapy (HR 0.40, p < 0.0001).
The company plans global regulatory submissions including a U.S. New Drug Application under a Commissioner’s National Priority Voucher and will present full data at ASCO 2026.
Revolution Medicines (NASDAQ:RVMD) has begun treating patients in RASolute 303, a global Phase 3 trial of daraxonrasib for previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).
The randomized, open-label study compares daraxonrasib as monotherapy and combined with gemcitabine plus nab-paclitaxel versus standard-of-care gemcitabine and nab-paclitaxel, enrolling patients irrespective of tumor RAS genotype. Primary endpoints are progression-free survival and overall survival. Daraxonrasib is being evaluated in four global Phase 3 registrational trials, including three in PDAC and one in NSCLC.
Revolution Medicines (Nasdaq:RVMD) will present nine oral and poster presentations at the AACR Annual Meeting, April 17–22, 2026 in San Diego. Highlights include Phase 1 zoldonrasib (G12D) data in KRAS G12D NSCLC (plenary) and Phase 1/2 daraxonrasib datasets in first-line metastatic PDAC (mini-symposium).
Presentations also cover a new class of catalytic RAS(ON) inhibitors addressing emergent resistance and multiple preclinical and clinical RAS(ON) research topics.
Revolution Medicines (Nasdaq: RVMD) reported Q4 and full-year 2025 results and clinical progress on Feb 25, 2026. The company holds $2.0 billion in cash and received a $250 million royalty tranche, with $1.75 billion more committed. R&D and G&A rose materially; net loss was $364.9M in Q4 and $1.1B for 2025. Full-year 2026 GAAP operating expense guidance is $1.6–1.7B.
Clinical highlights: RASolute 302 pivotal readout expected in H1 2026; five ongoing Phase 3 trials and three planned; initiated RASolute 305 and advanced RMC-5127 into first-in-human dosing. Zoldonrasib received FDA Breakthrough Therapy designation for G12D NSCLC.
Revolution Medicines (Nasdaq: RVMD) said CEO Mark A. Goldsmith, M.D., Ph.D., will take part in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 9:50 a.m. ET.
According to the company, a live webcast will be available and a replay will remain on the company website for at least 14 days.
Revolution Medicines (Nasdaq: RVMD) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026 after market close. A senior management webcast will begin at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and corporate progress. A replay will be available on the company website for at least 14 days.
Revolution Medicines (Nasdaq: RVMD) announced that Mark A. Goldsmith, M.D., Ph.D., CEO and chairman, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET.
According to the company, the session will be webcast live and a replay will be available on the company's investor website for at least 14 days following the event.
Revolution Medicines (NASDAQ:RVMD) announced dosing of the first patient in the first-in-human trial RMC-5127-001 (NCT07349537), evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor.
The open-label trial will assess safety, tolerability, pharmacokinetics and preliminary antitumor activity as monotherapy and in combination in patients with RAS G12V–mutated PDAC, CRC and NSCLC. RMC-5127 is the company’s fifth disclosed mutant-selective RAS(ON) inhibitor and fourth clinical-stage program, targeting an estimated ~48,000 U.S. patients diagnosed annually with RAS G12V–driven cancers.
Revolution Medicines (Nasdaq: RVMD) announced that the U.S. FDA granted Breakthrough Therapy Designation to zoldonrasib for adults with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD-1/PD-L1 therapy and platinum chemotherapy. The designation is based on data from the monotherapy cohort of the Phase 1 RMC-9805-001 trial, which demonstrated encouraging antitumor activity and acceptable safety and tolerability. Zoldonrasib is a tri-complex RAS(ON) G12D-selective covalent inhibitor that binds cyclophilin A. This is the first Breakthrough Therapy Designation for an investigational drug specifically targeting RAS G12D in NSCLC and follows prior designations for the company's daraxonrasib and elironrasib.